Company
February 2024: we are delighted to announce that NHG is preparing to commence the commercialisation of the patent-pending Male HPV test kit, known as ‘NanoSwab’, developed by NHLS at Hong Kong Science & Technology Park in collaboration with the Nano and Advanced Materials Institute Limited (NAMI). Additionally, this test kit has also been nominated as a finalist at the prestigious Edison Awards held in America, specifically in the category of Genomic and Stem Cell Innovations.
Please do not hesitate to reach out to us for discussions about research and/or commercialization.
NHLS: https://nh-lifesciences.com.hk/
NHG: https://neohealth.com.hk/
John D. Evans, Director (Innovation and Technology), Development and Commercialisation:
john.evans@neohealth.com.hk
Description
NHLS is a division of the Neo-Health Group (NHG), Asia’s foremost clinic for sexual health and the treatment of sexually transmitted infections (STIs). NHLS specifically focuses on driving research and development (R&D) initiatives, which is a distinctive aspect for medical clinics to undertake.
